

EuroSIDA Newsletter

May 2015



ANNOUNCEMENTS

Dear EuroSIDA Study Investigators,


The staff at the EuroSIDA coordinating centre would like to kindly thank you for your excellent work and continued contribution to the EuroSIDA study. Below, please find an update on the EuroSIDA study status.

Enrolment status for the new EuroSIDA cohort

We are happy to announce that [we have enrolled more than 3,000 patients](#) in cohort 10 to date. Cohort 10 is now the largest cohort to be included in EuroSIDA since the EuroSIDA study started back in 1994. Thank you all for contributing!

However, we still look to include 5,000 patients in the cohort, so [if you have not reached your target yet, please continue to enroll patients](#).

So far 3,130 patients, [62% of the currently target of 5,000, have been enrolled](#). 78 centres from 31 countries are so far contributing to the cohort and 32 centres have reached their enrolment target. The EuroSIDA team would like to thank these sites for their professional work done to complete the enrolment process.



Follow-up for cohort 10 patients

Cohort 10 patients who have been enrolled in REDCap before 1 April 2015 and have completed all enrolment data in REDCap by mid-May 2015 will be included in dataset 42. We anticipate that about 2,500 cohort 10 patients will be added to EuroSIDA follow-up in June. Please note that any new information on completed cohort 10 enrolment patients, should be reported in the next follow-up form in REDCap. Please do not add any new information if the patient has been completed in the 'Status section'.

Dataset 42

The next EuroSIDA dataset will be ready in early June 2015. Please note that REDCap dataset 41 has been closed for further data entry in REDCap in order to prepare for dataset 42. Please input any new information in the next follow-up dataset 42.

D:A:D event forms for cohort 10 patients

Please remember to complete and return D:A:D event forms for D:A:D events occurring on cohort 10 patients after baseline (enrolment date). D:A:D event forms can be found [HERE](#).

REDCap

We have had a number of questions from investigators concerning how to enter the REDCap system. Please be aware that CHIP is working with more than one REDCap system and for EuroSIDA the link to be used is [THIS](#).

Completing forms in REDCap

Please remember to [always complete all sections in REDCap for both enrolment and follow-up forms](#). If there is no new data, please report this in the form and choose 'complete' in the dropdown menu at the bottom.

Monitoring 2015

The monitoring season 2015 has started. We look forward to meeting you at the sites!

When to complete HCV Treatment and HCV Adverse Event forms

- **Patient under follow-up:** Please complete a *HCV Treatment form* if treatment was ongoing 1. June 2014 or has started after 1. June 2014.
- **Cohort 10 patients:** Please complete a *HCV Treatment form* if treatment was ongoing during enrolment or has started after enrolment (baseline).
- Please complete a *HCV Treatment Adverse Event form* if a patient stops treatment early due to toxicity/intolerance.

PUBLICATIONS

Publications since last newsletter April 2015

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons. N Friis-Møller, L Ryom, C Smith, R Weber, P Reiss, F Dabis, S De Wit, A D'Arminio Monforte, O Kirk, E Fontas, C Sabin, A Phillips, J Lundgren, M Law, on behalf of the D:A:D study group. *European Journal of Preventive Cardiology* 2015 Apr 16

Development and validation of a risk-score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. A Mocroft, JD Lundgren, M Ross, M Law, P Reiss, O Kirk, C Smith, D Wentworth, J Neuhaus, CA Fux, O Moranne, P Morlat, MA Johnson, L Ryom on behalf of the Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT, SMART and ESPRIT study group. *PIOS Medicine* 2015 Mar 31; 12 (3).

Liver-related death among HIV/HCV coinfecting individuals, implications for the era of directly acting antivirals. D Grint, L Peters, JK Rockstroh, A Rakmanova, T Trofimova, K Lacombe, I Karpov, M Galli, P Domingo, O Kirk, JD Lundgren, A. Mocroft for EuroSIDA in EuroCoord. *AIDS* 2015. *AIDS*. 2015 Apr 13. [Epub ahead of print]

Hepatitis C seroconversions in HIV infection across Europe: Which regions and patient groups are affected? Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Chentsova N, Hadziosmanovic V, Kirk O, Mocroft A, Peters L, Rockstroh JK; for EuroSIDA in EuroCoord. *Liver Int.* 2015 Apr 15. doi: 10.1111/liv.12848. [Epub ahead of print]

IN PRESS

Major differences in organisation and availability of healthcare and medicines for HIV/TB coinfecting patients across Europe. M Mansfeld, A Skrahina, L Shepherd, A Schultze, AM Panteleev, RF Miller, JM Miro, I Zeltina, S Tetradov, H Furrer, O Kirk, A Grzeszczuk, N Bolokadze, A Matteelli, FA Post, JD Lundgren, A Mocroft, AM W Efsen, DN Podlekareva for the TB:HIV study group in EuroCoord; *HIV Medicine*, January 2015. [In press].

Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA cohort. D. Podlekareva, D Grint, I. Karpov,

Internet access required for monitoring visits

This year the monitors will need an internet access to be able to monitor in the REDCap system. Please advise us if this is not possible at your site so we can make an alternative solution while monitoring at your site. Our monitors will bring their own laptops.

Update from EuroCoord

Please find the latest news from EuroCoord at:
newsletter at
www.eurocoord.net



A. Rakmanova, K Mansinho, N. Chentsova, I. Zeltina, M. Losso, M. Parczewski J. D. Lundgren, A. Mocroft, O. Kirk for EuroSIDA in EuroCoord [In press]

HIV resistance testing and detected drug resistance in Europe: Data from the EuroSIDA cohort 1997-2012. A Schultze, AN Phillips, R Paredes, M Battegay, JK Rockstroh, L Machala, J Tomazic, I Januskevica, PM Girard, K Laut, JD Lundgren, A Cozzi-Lepri. AIDS. 2015 April. (IF: 6.348) [In press]

EuroSIDA Coordinating Centre. Rigshospitalet, University of Copenhagen. CHIP, Department of Infectious Diseases, Section 2100, Finsencentret. Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.

Tel: +45 35 45 57 57. Fax: +45 35 45 57 58. E-mail: EuroSIDA.rigshospitalet@regionh.dk

Web: www.regionh.dk www.chip.dk

This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement n° 260694.